Expanded Adolescent and Young Adult Study - Extension

与年轻和老年癌症人口相比，SEER数据表明，15岁至39岁的青少年和年轻成人(Aya)人口的癌症存活率几十年来几乎没有改善。2005年，国家癌症研究所与兰斯·阿姆斯特朗基金会合作，成立了进展审查小组(PRG)，以解决阿亚癌症人群的特殊研究和癌症护理需求。PRG确定了与癌症护理提供相关的重要潜在因素，这些因素可能导致许多Aya癌症患者相对较差的结果，包括：患者获得护理的机会、诊断的延误、癌症治疗环境以及护理提供者使用的特定治疗做法。 利用SEER提供的数据，最近的青春期和青年癌症进展审查小组(PRG)报告确定，AYA的后续行动是高度优先的。虽然大多数年龄段的存活率一直在上升，但阿亚的存活率并没有增加。因此，PRG建议应特别重视收集这些被诊断为癌症的人的当前和完整的治疗数据。这些患者经常陷入儿童肿瘤学和成人肿瘤学之间的无人区。对AYA的研究进一步受到了限制，因为他们在相对较少的临床试验中的参与率非常低，部分原因是诊断医生很少让这些患者参加试验。护理方面的不一致，加上研究数据不足，阻碍了制定治疗和监测患有癌症的AYA的指南，而且几乎没有工具来衡量在不同环境中提供的治疗和心理社会干预的效果。PRG确定，在这一人群中进行研究是高度科学优先事项。 为了解决这些差距，我们已经组织了一个跨NCI和校外团队来计划一项可行性研究，从2007年10月开始纳入大约500名Aya患者。

Compared to younger and older aged cancer populations, SEER data suggest that the adolescent and young adult (AYA) population between the ages of 15 and 39 years has seen little or no improvement in cancer survival rates for decades. In 2005, the National Cancer Institute partnered with the Lance Armstrong Foundation and developed a Progress Review Group (PRG) to address the special research and cancer care needs of the AYA cancer population. The PRG identified important potential factors related to cancer care delivery that may contribute to the poorer relative outcome for many AYA cancer patients including: the patient access to care, delays in diagnosis, the cancer treatment setting and specific treatment practices used by care providers. Using the data provided by SEER the recent Progress Review Group (PRG) Report on Cancer in Adolescent and Young Adults (AYA) determined that follow-up of AYA was a high priority. While survival has been increasing for most age groups, it has not for AYA. Therefore, the PRG suggested a special emphasis should be placed on collection of current and complete treatment data for these individuals diagnosed with cancer. These patients too frequently fall into a ¿no man's land¿ between pediatric and adult oncology. Research on AYAs has been further constrained by their exceedingly low participation in the relatively few clinical trials available to them, in part because diagnosing physicians seldom refer these patients to trials. Inconsistency in care, coupled with insufficient research data, has prevented the development of guidelines for treating and monitoring AYAs with cancer, and few tools exist to measure the efficacy of treatment and psychosocial interventions delivered in diverse settings. The PRG determined that research in this population was a high scientific priority. To address these gaps, we have assembled a trans-NCI and extramural team to plan a feasibility study to include approximately 500 AYA patients beginning in October 2007.